Eiger BioPharmaceuticals, Inc. (EIGRQ)
OTCMKTS
· Delayed Price · Currency is USD
8.50
0.00 (0.00%)
Inactive · Last trade price
on Oct 1, 2024
Eiger BioPharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 15.52 | 15.52 | 12.73 | 12.14 | - | - | Upgrade
|
| Other Revenue | 0.25 | 0.25 | 0.75 | - | - | - | Upgrade
|
| Revenue | 15.77 | 15.77 | 13.48 | 12.14 | - | - | Upgrade
|
| Revenue Growth (YoY) | 16.98% | 16.98% | 11.05% | - | - | - | Upgrade
|
| Cost of Revenue | 0.02 | 0.02 | 1.84 | 0.75 | - | - | Upgrade
|
| Gross Profit | 15.75 | 15.75 | 11.65 | 11.4 | - | - | Upgrade
|
| Selling, General & Admin | 25.2 | 25.2 | 29.11 | 23.9 | 20.56 | 17.11 | Upgrade
|
| Research & Development | 62.33 | 62.33 | 75.28 | 64.44 | 41.59 | 51.79 | Upgrade
|
| Operating Expenses | 87.54 | 87.54 | 104.39 | 88.34 | 62.15 | 68.9 | Upgrade
|
| Operating Income | -71.79 | -71.79 | -92.74 | -76.94 | -62.15 | -68.9 | Upgrade
|
| Interest Expense | -5.47 | -5.47 | -4.13 | -3.56 | -3.59 | -3.41 | Upgrade
|
| Interest & Investment Income | 2.21 | 2.21 | 1.08 | 0.16 | 0.7 | 2.07 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.09 | 0.09 | 0.14 | 46.49 | -0.01 | -0.02 | Upgrade
|
| EBT Excluding Unusual Items | -74.96 | -74.96 | -95.65 | -33.85 | -65.05 | -70.25 | Upgrade
|
| Other Unusual Items | - | - | -1.1 | - | - | - | Upgrade
|
| Pretax Income | -74.96 | -74.96 | -96.75 | -33.85 | -65.05 | -70.25 | Upgrade
|
| Income Tax Expense | 0.01 | 0.01 | 0.02 | 0.06 | - | - | Upgrade
|
| Net Income | -74.96 | -74.96 | -96.78 | -33.92 | -65.05 | -70.25 | Upgrade
|
| Net Income to Common | -74.96 | -74.96 | -96.78 | -33.92 | -65.05 | -70.25 | Upgrade
|
| Shares Outstanding (Basic) | 1 | 1 | 1 | 1 | 1 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 1 | 1 | 1 | 1 | 1 | 1 | Upgrade
|
| Shares Change (YoY) | 6.39% | 6.39% | 22.64% | 20.61% | 23.51% | 67.12% | Upgrade
|
| EPS (Basic) | -50.78 | -50.78 | -69.74 | -29.98 | -69.34 | -92.50 | Upgrade
|
| EPS (Diluted) | -50.78 | -50.78 | -69.74 | -29.98 | -69.34 | -92.50 | Upgrade
|
| Free Cash Flow | -74.78 | -74.78 | -83.35 | -71.57 | -63.44 | -64.09 | Upgrade
|
| Free Cash Flow Per Share | -50.66 | -50.66 | -60.07 | -63.25 | -67.63 | -84.38 | Upgrade
|
| Gross Margin | 99.85% | 99.85% | 86.38% | 93.86% | - | - | Upgrade
|
| Operating Margin | -455.12% | -455.12% | -687.78% | -633.66% | - | - | Upgrade
|
| Profit Margin | -475.26% | -475.26% | -717.71% | -279.34% | - | - | Upgrade
|
| Free Cash Flow Margin | -474.11% | -474.11% | -618.14% | -589.42% | - | - | Upgrade
|
| EBITDA | -71.51 | -71.51 | -92.45 | -76.66 | -61.98 | -68.84 | Upgrade
|
| D&A For EBITDA | 0.28 | 0.28 | 0.29 | 0.28 | 0.17 | 0.07 | Upgrade
|
| EBIT | -71.79 | -71.79 | -92.74 | -76.94 | -62.15 | -68.9 | Upgrade
|
| Revenue as Reported | 15.77 | 15.77 | 13.48 | 12.14 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.